Kidney Repair Clinical Trials - Biopsy Phase
December 15, 2020
Organ injuries and diseases are a leading cause of death. A current medical solution is an organ transplant. However, Autologous Regenerative Tissue Replacement (ARTR™) organ repair treatment, an attractive alternative, is now in clinical trials.
BCM Industries has developed a new organ “Repair-In-Place” (“In-Situ”), repair approach to failing and injured organs. Using the patient’s own organ cells and advanced human tissue engineering technologies, the BCM team designs a patient tailored, collagen scaffold, upon which a large army of new healthy patient cells are grown.
This large “In vitro” army of patent cells are surgically implanted onto the patient’s defective organ. This army of cells are the patient’s own cells; there is no rejection and there is no need for any type of immune system suppression or anti-rejection drug treatment.
Upon implant, this army of cells is immediately accepted by the patient’s organ and these new healthy cells begin to rapidly and massively multiple. As the army of cells continues to expand, it quickly replaces older weaker cells and proceeds to regenerate the failing organ.
A video introduction to the surgical team and the initial biopsy procedure for an ARTR™ kidney repair below.
To learn more about the BCM organ repair “In-Place” approach and how it may be able to aid you or someone you know, visit the BCM Industries website: BCMIndustries.com
BCM Industries is an emerging industry leader in regenerative tissue replacement medical products with specific emphasis upon the creation and delivery of advanced Autologous Regenerative Tissue Replacement (ARTR™) products, processes and technologies, and other products and services to the global healthcare community.
